Clin2
NCT06713616Possibly a fitRecruiting

Esketamine vs. ketamine for hard-to-treat depression

Depression

Part of Mental health clinical trials.

This study compares the effectiveness of esketamine (Spravato) and another similar drug, ketamine, for adults with major depression that has not improved after trying at least two other antidepressants. It aims to find out which treatment works better.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
400 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have major depression that hasn't gotten better with at least two prior antidepressant treatments
  • Your depression is moderate to severe as measured by a standard rating scale
  • You are not pregnant, breastfeeding, or of childbearing potential without using highly effective birth control
  • You do not have bipolar disorder or a psychotic disorder
  • You do not have a current or recent substance use disorder (except nicotine) and haven't had too many prior ketamine or esketamine treatments

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03973268Recruiting· Phase 1
Ketamine study to understand treatment response in hard-to-treat depression

This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.

Bethesda, Maryland
NCT06725277Recruiting
Observing ketamine and Spravato for depression

This study follows people who are already taking or about to start IV ketamine or Spravato® for hard-to-treat depression. Researchers want to learn more about how these treatments work in real life.

Milford, Connecticut
NCT06788249Recruiting· Early Phase 1
Ketamine for treatment-resistant depression brain study

This trial tests whether a single dose of ketamine can quickly improve depression by studying brain chemical changes using MRI. It's for people with treatment-resistant depression who haven't used ketamine before.

Philadelphia, Pennsylvania
NCT06213324Recruiting· Phase 4
Ketamine's effects on brain circuits in depression

This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.

New York, New York
NCT07307768Not yet recruiting· Phase 1
Ketamine Biomarker Study for Severe Depression

This trial is for people with severe major depression who may benefit from a single dose of ketamine. Researchers want to see if certain biomarkers in your blood or brain can predict how well ketamine works for you.

New York, New York
NCT06559826Recruiting· Phase 2
Ketamine therapy with or without talk for depression

This study compares ketamine alone to ketamine combined with psychotherapy for treating depression. It may help if you have moderate to severe depression and want to see if adding talk therapy improves results.

New York, New York

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.